HER2 Biomarkers
Reveal Genomics, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials
The partners aim to improve understanding of early-stage HER2-positive breast cancer patients and gain insights into optimal treatment strategies.
The test is already available commercially in Spain, and the company intends to next launch its offering in Italy, as it expands to other European markets.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium
New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.